Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending its shares down nearly 17% in extended trading.
The drug, brensocatib, failed to meet the main goal of improving sinus-related symptoms such as nasal congestion in patients with chronic rhinosinusitis without nasal polyps, an inflammatory condition of the sinuses.
https://ca.finance.yahoo.com/news/insmed-scraps-development-sinus-drug-223511785.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.